Discussion

Response required for below Student 1 comment:

If I am the manufacturer of the drugs, I will not voluntarily disclose the study information. I would have to use my expertise to make this decision. This would constitute a clear breach of my ethical obligation as a member of society to disclose information relevant to medical research that may harm society. I believe that the study is essential and will take it to the regulatory authorities if necessary. This information could provide potential competitors with a competitive advantage through anti-competitive pricing or by giving them the edge from a lack of competition (Costel et al., 2017). This is a significant concern for pharmaceutical companies. The problem for society, in general, is that companies might use the information they gain from marketing for their purposes.

I might not disclose it until legal protections have been exhausted. This is because of risks associated with the confidentiality of the study and the potential harm of disclosure. The confidentiality protection of research data is a federal mandate. Although there are many methods of conducting personal research and therefore must be kept confidential, there are specific requirements regarding confidentiality. However, the companies involved in the marketing and research must be aware that, in the case of safety or effectiveness claims on pharmaceutical products, they must be highly cautious when divulging trade secrets. Pharmaceutical companies are responsible for developing and quality the drugs in a country, and a thorough understanding of their product is essential for successful marketing (Chang et al., 2017). Thus, the information available in the public domain is being used by the government to secure its information infrastructure and protect its assets and reputation and those individuals or organizations who wish to create new innovative technologies.

 

 

References

Chang, J. C., Holland, C. L., Tarr, J. A., Rubio, D., Rodriguez, K. L., Kraemer, K. L., ... & Arnold, R. M. (2017). Perinatal illicit drug and marijuana use: an observational study examines the prevalence, screening, and disclosure. American Journal of Health Promotion, 31(1), 35-42.

Costello, K. L., Martin III, J. D., & Edwards Brinegar, A. (2017). Online disclosure of illicit information: Information behaviors in two drug forums. Journal of the Association for Information Science and Technology, 68(10), 2439-2448.